FDA OKs Combo Treatment for Cystic Fibrosis Caused by Certain Mutations

Original post, click here
Share this...
Tweet about this on TwitterShare on FacebookShare on LinkedInEmail this to someoneShare on Google+Share on RedditPin on Pinterest

FDA officials have approved tezacaftor/ivacaftor and ivacaftor (Symdeko, Vertex Pharmaceuticals) for the treatment of cystic fibrosis (CF) in individuals aged 12 years and older.